Correlation between white blood cell count and mood-stabilising treatment response in two bipolar disorder trials.
bipolar disorder
lithium
quetiapine
treatment response
white blood cell
Journal
Acta neuropsychiatrica
ISSN: 1601-5215
Titre abrégé: Acta Neuropsychiatr
Pays: England
ID NLM: 9612501
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
pubmed:
7
6
2019
medline:
10
1
2020
entrez:
7
6
2019
Statut:
ppublish
Résumé
Immune system markers may predict affective disorder treatment response, but whether an overall immune system marker predicts bipolar disorder treatment effect is unclear. Bipolar CHOICE (N = 482) and LiTMUS (N = 283) were similar comparative effectiveness trials treating patients with bipolar disorder for 24 weeks with four different treatment arms (standard-dose lithium, quetiapine, moderate-dose lithium plus optimised personalised treatment (OPT) and OPT without lithium). We performed secondary mixed effects linear regression analyses adjusted for age, gender, smoking and body mass index to investigate relationships between pre-treatment white blood cell (WBC) levels and clinical global impression scale (CGI) response. Compared to participants with WBC counts of 4.5-10 × 109/l, participants with WBC < 4.5 or WBC ≥ 10 showed similar improvement within each specific treatment arm and in gender-stratified analyses. An overall immune system marker did not predict differential treatment response to four different treatment approaches for bipolar disorder all lasting 24 weeks.
Sections du résumé
BACKGROUND
BACKGROUND
Immune system markers may predict affective disorder treatment response, but whether an overall immune system marker predicts bipolar disorder treatment effect is unclear.
METHODS
METHODS
Bipolar CHOICE (N = 482) and LiTMUS (N = 283) were similar comparative effectiveness trials treating patients with bipolar disorder for 24 weeks with four different treatment arms (standard-dose lithium, quetiapine, moderate-dose lithium plus optimised personalised treatment (OPT) and OPT without lithium). We performed secondary mixed effects linear regression analyses adjusted for age, gender, smoking and body mass index to investigate relationships between pre-treatment white blood cell (WBC) levels and clinical global impression scale (CGI) response.
RESULTS
RESULTS
Compared to participants with WBC counts of 4.5-10 × 109/l, participants with WBC < 4.5 or WBC ≥ 10 showed similar improvement within each specific treatment arm and in gender-stratified analyses.
CONCLUSIONS
CONCLUSIONS
An overall immune system marker did not predict differential treatment response to four different treatment approaches for bipolar disorder all lasting 24 weeks.
Identifiants
pubmed: 31169098
pii: S092427081900019X
doi: 10.1017/neu.2019.19
doi:
Substances chimiques
Antimanic Agents
0
Quetiapine Fumarate
2S3PL1B6UJ
Lithium
9FN79X2M3F
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM